B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini,Bernard Escudier,Piotr Tomczak,Andrey Kaprin,Cezary Szczylik,Thomas E. Hutson,M. Dror Michaelson,Vera Gorbunova,Martin Gore,Igor G. Rusakov,Sylvie Negrier,Yen Chuan Ou,Daniel Castellano,Ho Yeong Lim,Hirotsugu Uemura,Jamal Tarazi,David Cella,Connie Chen,Brad Rosbrook,Sinil Kim,Robert J. Motzer +20 more
TL;DR: Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib.
Journal ArticleDOI
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer,Konstantin Penkov,John B. A. G. Haanen,Brian I. Rini,Laurence Albiges,Matthew T. Campbell,Balaji Venugopal,Christian Kollmannsberger,Sylvie Negrier,Motohide Uemura,Jae L. Lee,Aleksandr Vasiliev,Wilson H. Miller,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Jens Bedke,Boris Alekseev,Jing Wang,Mariangela Mariani,Paul B. Robbins,Aleksander Chudnovsky,Camilla Fowst,Subramanian Hariharan,Bo Huang,Alessandra di Pietro,Toni K. Choueiri +27 more
TL;DR: Progression‐free survival was significantly longer with avelumab plus axitinib than with sunit inib among patients who received these agents as first‐line treatment for advanced renal‐cell carcinoma.
Journal ArticleDOI
Renal cell carcinoma
TL;DR: The effectiveness of immunotherapy, although previously widely used for treatment of metastatic renal cell carcinoma, is still controversial, and is mainly reserved for patients with good prognostic factors as discussed by the authors.